We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-7.64%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$563M
AUM Growth
-$101M
(-15%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-4.8%
Top 10 Holdings %
Top 10 Hldgs %
25.13%
Holding
123
New
15
Increased
30
Reduced
43
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$13.2M |
| 2 |
HealthEquity
HQY
|
+$13M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$7.95M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$7.45M |
| 5 |
ITOS
iTeos Therapeutics
ITOS
|
+$5.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$21.4M |
| 2 |
Alignment Healthcare
ALHC
|
+$10.3M |
| 3 |
Definitive Healthcare
DH
|
+$7.8M |
| 4 |
TG Therapeutics
TGTX
|
+$7.6M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
+$6.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.69% |
| 2 | Industrials | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Medtronic
MDT
$111B
| $2.5M | 0.44% |
22,551
-24,150
| -52% | -$2.55M |
|
77
Jasper Therapeutics
JSPR
$20.2M
| $2.4M | 0.43% |
+67,500
| New | +$3.04M |
|
|
TRML
78
DELISTED
Tourmaline Bio
TRML
| $2.25M | 0.4% |
22,862
-3,196
| -12% | -$299K |
|
79
Regeneron Pharmaceuticals
REGN
$78.2B
| $2.12M | 0.38% |
3,040
-370
| -11% | -$234K |
|
80
Bristol-Myers Squibb
BMY
$134B
| $2.04M | 0.36% |
+28,000
| New | +$1.88M |
|
81
Sight Sciences
SGHT
$301M
| $1.97M | 0.35% |
170,000
| – | – |
|
82
Vertex Pharmaceuticals
VRTX
$119B
| $1.9M | 0.34% |
7,281
-490
| -6% | -$116K |
|
83
Edwards Lifesciences
EW
$51.1B
| $1.87M | 0.33% |
15,850
+4,850
| +44% | +$544K |
|
84
Stryker
SYK
$131B
| $1.86M | 0.33% |
6,950
-1,650
| -19% | -$427K |
|
|
BTTX
85
DELISTED
Better Therapeutics, Inc. Common Stock
BTTX
| $1.74M | 0.31% |
878,531
-95,302
| -10% | -$329K |
|
|
CMPI
86
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $1.73M | 0.31% |
541,765
-1
| -0% | -$3 |
|
87
Gilead Sciences
GILD
$163B
| $1.49M | 0.26% |
25,000
+2,100
| +9% | +$134K |
|
88
Align Technology
ALGN
$12.4B
| $1.05M | 0.19% |
2,415
-5,850
| -71% | -$2.85M |
|
|
PROC
89
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
| $929K | 0.16% |
109,245
-109,999
| -50% | -$990K |
|
|
ONC
90
BeOne Medicines Ltd
ONC
$32.6B
| $864K | 0.15% |
4,580
-200
| -4% | -$42.5K |
|
91
Ascendis Pharma A/S
ASND
$16B
| $719K | 0.13% |
6,129
| – | – |
|
92
Illumina
ILMN
$29.9B
| $685K | 0.12% |
2,015
-2,056
| -51% | -$694K |
|
93
Alnylam Pharmaceuticals
ALNY
$29.5B
| $665K | 0.12% |
4,070
-3,526
| -46% | -$537K |
|
94
Icon
ICLR
$12.2B
| $535K | 0.1% |
2,200
| – | – |
|
95
Zai Lab
ZLAB
$2.05B
| $528K | 0.09% |
12,000
+3,000
| +33% | +$145K |
|
96
Agilent Technologies
A
$39.5B
| $503K | 0.09% |
3,800
-300
| -7% | -$41.3K |
|
97
Incyte
INCY
$24B
| $465K | 0.08% |
5,860
| – | – |
|
98
BioNTech
BNTX
$23.3B
| $447K | 0.08% |
2,620
-335
| -11% | -$56.3K |
|
|
SONX
99
DELISTED
Sonendo, Inc.
SONX
| $437K | 0.08% |
108,869
-236,148
| -68% | -$1.31M |
|
100
Legend Biotech
LEGN
$3.68B
| $436K | 0.08% |
12,000
+5,000
| +71% | +$198K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Sectoral Asset Management held 123 positions worth $563M, down 15% from $664M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Sectoral Asset Management withdrew a net $27M in Q1 2022, closing 17 positions and reducing 43 holdings. Its most notable exit was Arena Pharmaceuticals Inc, an estimated $21.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials.
Against the trend, Sectoral Asset Management opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $12.6M.
- Sectoral Asset Management's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 105,850 shares worth $12.6M.
- Sectoral Asset Management added most to BioMarin Pharmaceuticals in Q1 2022, an estimated $7.95M increase.
- Sectoral Asset Management's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $5.8M.
- Sectoral Asset Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $21.4M.
- Sectoral Asset Management's ten largest holdings make up 25% of its $563M portfolio in Q1 2022.
- Sectoral Asset Management opened 15 new positions and closed 17 in Q1 2022.
- Sectoral Asset Management's portfolio value fell 15% quarter-over-quarter to $563M.
Based on Sectoral Asset Management's 13F filing for Q1 2022, filed 10 May 2022.